Inhibitors of leukotriene A4 hydrolase
US9822106B2 · kind B2 · utility
1Cited by
32References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 10, 2015 |
| Grant date | Nov 21, 2017 |
| Priority date | — |
| Expiry date | Sep 10, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.